Overview Dividends

(EXPO) Exponent - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30214U1025

Consulting, Engineering, Sciences, Safety, Regulatory

EXPO EPS (Earnings per Share)

EPS Growth (3Y CAGR): 6.26%
EPS Trend (3Y Correlation): 21.1%

EXPO Revenue

Revenue Growth (3Y CAGR): 3.64%
Revenue Trend (3Y Correlation): 64.2%

Risk via 10d forecast
Volatility	26.1%
Value at Risk 5%th	39.7%
Relative Tail Risk	-7.77%

Reward TTM
Sharpe Ratio	-1.60
Alpha	-40.50

Character TTM
Hurst Exponent	0.241
Beta	0.535
Beta Downside	0.274

Drawdowns 3y
Max DD	42.55%
Mean DD	20.06%
Median DD	19.50%

Description: EXPO Exponent November 08, 2025

Exponent, Inc. (NASDAQ: EXPO) is a science-and-engineering consulting firm that serves a broad spectrum of industries-including chemical, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, transportation, and more-through two primary segments: Engineering & Other Scientific, and Environmental & Health.

The firm’s service portfolio spans biomechanics, biomedical engineering, civil & structural engineering, data science, electrical & computer engineering, human factors, materials & corrosion engineering, polymer science, thermal sciences, vehicle engineering, as well as chemical regulation, food safety, ecological and biological sciences, environmental & earth sciences, and health sciences. It also provides proactive and reactive product-safety, litigation-support, and regulatory consulting.

Key recent metrics (FY 2023): revenue of approximately $1.2 billion, operating margin around 12 %, and a backlog of roughly $1.0 billion, indicating a stable pipeline of multi-year contracts. The company’s litigation-support business has grown ~8 % YoY, driven by heightened product-liability activity across consumer and medical device sectors.

Macro-level drivers that could influence Exponent’s outlook include the U.S. Infrastructure Investment and Jobs Act, which is expected to boost demand for civil and structural engineering consulting, and tightening environmental regulations that increase the need for compliance and sustainability expertise across manufacturing and energy firms.

For a deeper dive into Exponent’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-rich overview worth checking out.

EXPO Stock Overview

Market Cap in USD	3,489m
Sub-Industry	Research & Consulting Services
IPO / Inception	1990-08-17
Return 12m vs S&P 500	-36.1%
Analyst Rating	3.67 of 5

EXPO Dividends

Dividend Yield	1.69%
Yield on Cost 5y	1.52%
Yield CAGR 5y	10.18%
Payout Consistency	100.0%
Payout Ratio	59.4%

EXPO Growth Ratios

CAGR 3y	-10.83%
CAGR/Max DD Calmar Ratio	-0.25
CAGR/Mean DD Pain Ratio	-0.54
Current Volume	382.9k
Average Volume	335.9k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (104.8m TTM) > 0 and > 6% of Revenue (6% = 34.3m TTM)

FCFTA 0.22 (>2.0%) and ΔFCFTA 0.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 45.86% (prev 48.50%; Δ -2.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 132.2m > Net Income 104.8m (YES >=105%, WARN >=100%)

Net Debt (-124.8m) to EBITDA (149.5m) ratio: -0.83 <= 3.0 (WARN <= 3.5)

Current Ratio 2.69 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.5m) change vs 12m ago -0.33% (target <= -2.0% for YES)

Gross Margin 40.33% (prev 25.70%; Δ 14.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 86.90% (prev 76.16%; Δ 10.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' 10.17

(A) 0.46 = (Total Current Assets 416.8m - Total Current Liabilities 154.8m) / Total Assets 570.9m

(B) 1.15 = Retained Earnings (Balance) 658.8m / Total Assets 570.9m

warn (B) unusual magnitude: 1.15 — check mapping/units

(D) 1.83 = Book Value of Equity 656.5m / Total Liabilities 358.6m

Total Rating: 10.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.62

1. Piotroski 7.0pt = 2.0

2. FCF Yield 3.65% = 1.83

3. FCF Margin 21.51% = 5.38

4. Debt/Equity 0.21 = 2.48

5. Debt/Ebitda -0.83 = 2.50

6. ROIC - WACC (= 16.86)% = 12.50

7. RoE 24.77% = 2.06

8. Rev. Trend 64.22% = 4.82

9. EPS Trend 21.13% = 1.06

What is the price of EXPO shares?

As of November 17, 2025, the stock is trading at USD 69.94 with a total of 382,940 shares traded.
Over the past week, the price has changed by -1.20%, over one month by +2.48%, over three months by +1.60% and over the past year by -26.09%.

Is Exponent a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Exponent (NASDAQ:EXPO) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.62 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXPO is around 59.03 USD . This means that EXPO is currently overvalued and has a potential downside of -15.6%.

Is EXPO a buy, sell or hold?

Exponent has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold EXPO.

Strong Buy: 1
Buy: 0
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EXPO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	83	18.7%
Analysts Target Price	83	18.7%
ValueRay Target Price	65.5	-6.4%

EXPO Fundamental Data Overview November 17, 2025

Market Cap USD = 3.49b (3.49b USD * 1.0 USD.USD)
P/E Trailing = 34.4532
P/E Forward = 31.348
P/S = 6.5691
P/B = 8.6608
P/EG = 3.14
Beta = 0.824
Revenue TTM = 571.4m USD
EBIT TTM = 144.5m USD
EBITDA TTM = 149.5m USD
Long Term Debt = 82.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 82.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.36b USD (3.49b + Debt 82.6m - CCE 207.4m)
Interest Coverage Ratio = unknown (Ebit TTM 144.5m / Interest Expense TTM 0.0)
FCF Yield = 3.65% (FCF TTM 122.9m / Enterprise Value 3.36b)
FCF Margin = 21.51% (FCF TTM 122.9m / Revenue TTM 571.4m)
Net Margin = 18.35% (Net Income TTM 104.8m / Revenue TTM 571.4m)
Gross Margin = 40.33% ((Revenue TTM 571.4m - Cost of Revenue TTM 340.9m) / Revenue TTM)
Gross Margin QoQ = 24.94% (prev 16.43%)
Tobins Q-Ratio = 5.89 (Enterprise Value 3.36b / Total Assets 570.9m)
Interest Expense / Debt = 7.77% (Interest Expense 6.42m / Debt 82.6m)
Taxrate = 27.38% (10.6m / 38.6m)
NOPAT = 105.0m (EBIT 144.5m * (1 - 27.38%))
Current Ratio = 2.69 (Total Current Assets 416.8m / Total Current Liabilities 154.8m)
Debt / Equity = 0.21 (Debt 82.6m / totalStockholderEquity, last quarter 402.9m)
Debt / EBITDA = -0.83 (Net Debt -124.8m / EBITDA 149.5m)
Debt / FCF = -1.02 (Net Debt -124.8m / FCF TTM 122.9m)
Total Stockholder Equity = 423.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.36% (Net Income 104.8m / Total Assets 570.9m)
RoE = 24.77% (Net Income TTM 104.8m / Total Stockholder Equity 423.3m)
RoCE = 28.57% (EBIT 144.5m / Capital Employed (Equity 423.3m + L.T.Debt 82.6m))
RoIC = 24.79% (NOPAT 105.0m / Invested Capital 423.3m)
WACC = 7.94% (E(3.49b)/V(3.57b) * Re(7.99%) + D(82.6m)/V(3.57b) * Rd(7.77%) * (1-Tc(0.27)))
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 77.93% ; FCFE base≈135.1m ; Y1≈131.9m ; Y5≈133.3m
Fair Price DCF = 47.47 (DCF Value 2.37b / Shares Outstanding 49.9m; 5y FCF grow -3.46% → 3.0% )
EPS Correlation: 21.13 | EPS CAGR: 6.26% | SUE: -0.20 | # QB: 0
Revenue Correlation: 64.22 | Revenue CAGR: 3.64% | SUE: 1.13 | # QB: 1

Additional Sources for EXPO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle